Substituted 5-fluoro-1H-pyrazolopyridines and their use
The present application relates to novel substituted 5-fluoro-1H-pyrazolopyridines, to processes for their preparation, to their use alone or in combinations for the treatment and/or prophylaxis of diseases, and to their use for producing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular disorders.
1. A compound of the formula (I-A)
2. A pharmaceutical formulation comprising the compound of claim 1 and an inert, non-toxic, pharmaceutically suitable excipient.
3. A pharmaceutical composition comprising the compound of claim 1 and a further active compound selected from the group consisting of an organic nitrate, an NO donor, a cGMP-PDE inhibitor, an agent having antithrombotic activity, an agent for lowering blood pressure, and an agent for altering lipid metabolism.
4. A pharmaceutical formulation comprising the compound of formula (I-A)
or a salt thereof and an inert, non-toxic, pharmaceutically suitable excipient.
5. The pharmaceutical formulation of claim 4 comprising the salt of the compound of formula (I-A).
6. A pharmaceutical composition comprising the compound of formula (I-A)
or a salt thereof and a further active compound selected from the group consisting of an organic nitrate, an NO donor, a cGMP-PDE inhibitor, an agent having antithrombotic activity, an agent for lowering blood pressure, and an agent for altering lipid metabolism.
7. The pharmaceutical composition of claim 6 comprising the salt of the compound of formula (I-A).